Ligandrol
Based on 2 publication(s) in Google Scholar
Ligandrol is an orally active, selective androgen receptor (AR) agonist. Ligandrol enhances protein synthesis, inhibits muscle breakdown and oxidative stress, improves muscle cell viability and bone tissue microstructure, and reduces Cisplatin (HY-17394)-induced muscle toxicity and apoptosis. Ligandrol promotes muscle growth, protects bone structure, and has anti-diabetic, anti-apoptotic and antioxidant effects. Ligandrol can antagonize Streptozotocin (HY-13753) damage to pancreatic islets and improve the symptoms of type 2 diabetes.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.93%
- CAS No.: 1165910-22-4
- Formule: C14H12F6N2O
- Masse moléculaire:338.25
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Transcription Factor-Targeted Library
HY-L090
-
Nuclear Receptor Compound Library
HY-L126
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Ligandrol
MoreVoir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
|
Caspase 3 |
Caspase-7 |
Ligandrol increases insulin secretion in MIN6 cells within 2 hours exprouse[1].
Ligandrol (0.5-50 mg/L; 24 h) increased cell viability, total antioxidant capacity (TAC) and caspase 3/7 expression in a concentration-dependent manner, and decreased lactate dehydrogenase (LDH) release, total oxidative state (TOS), DNA fragmentation, lipid peroxidation and intracellular calcium concentration in the mouse skeletal muscle cell line C2C12[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mouse C2C12 skeletal muscle cells
-
Concentration:0.5, 5, 50 mg/L (Ligandrol); 10 μM (Cisplatin)
-
Incubation Time:24 h
-
Result:Had no significant cytotoxicity, but co-treatment with Cisplatin significantly increased cell viability by 1.1-2.14-fold compared to Cisplatin alone.
Reduced LDH release, a marker of membrane damage, by 1.16-2.18-fold in Ligandrol + Cisplatin groups, indicating improved membrane integrity.
Ligandrol (0.5 mg/kg; oral gavage; once daily; 3 weeks) improves muscle strength and function, increases muscle mass, and reduces Cisplatin (HY-17394)-induced oxidative stress and apoptosis in a mouse model of muscle atrophy[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cisplatin-Induced Muscle Atrophy Model (male, 25 g, 8 weeks old)[2]
-
Dosage:0.5 mg/kg
-
Administration:Oral gavage, once daily for 3 weeks
-
Result:-Muscle Strength and Function:
Significantly increased the grip strength of the mice than that in the Cisplatin-only group, indicating improved muscle strength. Enhanced the performance in the rotarod test, suggesting better muscle function.
-Muscle Mass:
Increased the weight of the gastrocnemius and quadriceps muscles compared to the Cisplatin-only group, demonstrating an increase in muscle mass.
-Oxidative Stress:
Decreased the levels of malondialdehyde (MDA), a marker of lipid peroxidation in the muscle tissues, while the activities of superoxide dismutase (SOD) and catalase (CAT) were increased, indicating a reduction in oxidative stress.
-Apoptosis:
Significantly decreased the number of apoptotic cells in the muscle tissues, as determined by TUNEL staining, than in the Cisplatin-only group. Decreased the expression of pro-apoptotic proteins such as Bax, while increased the expression of anti-apoptotic protein Bcl-2, suggesting apoptosis inhibition in muscle cells.
Chemical Information
-
CAS No. 1165910-22-4
-
Appearance Solid
-
Masse moléculaire 338.25
-
Formule C14H12F6N2O
-
Color White to off-white
-
SMILES
FC(F)(F)[C@@H]([C@]1([H])N(C2=CC(C(F)(F)F)=C(C=C2)C#N)CCC1)O
-
Synonyms
LGD-4033
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Drug Test Anal
High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction. [Abstract]2021 Feb;13(2):283-298. PMID: 32852861 -
Rapid Commun Mass Spectrom
Detection of LGD-4033 Metabolites in Camel Urine, Plasma, and Hair Following Oral Administration for Doping Control. [Abstract]2025 Apr 30;39(8):e9989. PMID: 39822140
Solvant et solubilité
DMSO : ≥ 100 mg/mL (295.64 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Sugumar D, et al. Ligandrol Ameliorates High-Fat Diet- and Streptozotocin-Induced Type 2 Diabetes Mellitus and Prevents Pancreatic Islets Degeneration. Assay Drug Dev Technol. 2024 Nov-Dec;22(8):397-408. [Content Brief]
[3]. Hoffmann DB, et al. Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis. J Bone Miner Metab. 2023 Nov;41(6):741-751. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9564 mL | 14.7819 mL | 29.5638 mL | 73.9096 mL |
| 5 mM | 0.5913 mL | 2.9564 mL | 5.9128 mL | 14.7819 mL | |
| 10 mM | 0.2956 mL | 1.4782 mL | 2.9564 mL | 7.3910 mL | |
| 15 mM | 0.1971 mL | 0.9855 mL | 1.9709 mL | 4.9273 mL | |
| 20 mM | 0.1478 mL | 0.7391 mL | 1.4782 mL | 3.6955 mL | |
| 25 mM | 0.1183 mL | 0.5913 mL | 1.1826 mL | 2.9564 mL | |
| 30 mM | 0.0985 mL | 0.4927 mL | 0.9855 mL | 2.4637 mL | |
| 40 mM | 0.0739 mL | 0.3695 mL | 0.7391 mL | 1.8477 mL | |
| 50 mM | 0.0591 mL | 0.2956 mL | 0.5913 mL | 1.4782 mL | |
| 60 mM | 0.0493 mL | 0.2464 mL | 0.4927 mL | 1.2318 mL | |
| 80 mM | 0.0370 mL | 0.1848 mL | 0.3695 mL | 0.9239 mL | |
| 100 mM | 0.0296 mL | 0.1478 mL | 0.2956 mL | 0.7391 mL |
Ligandrol Related Classifications
HY-13981 Related Classifications
Powered by Bioz